Q1 27 EPS Adjusted
$1.14
Q1 27 Revenue
$339.4M
vs S&P Since Q1 27
+8.7%
BEATING MARKET
HAE +9.3% vs S&P +0.5%
Market Reaction
Did HAE Beat Earnings? Q1 2027 Results
Haemonetics kicked off fiscal 2027 on solid footing, posting first-quarter revenue of $339.38 million, up 5.6% year-over-year, and adjusted EPS of $1.14, marking the company's fourth consecutive quarter of beating consensus EPS estimates. The standou… Read more Haemonetics kicked off fiscal 2027 on solid footing, posting first-quarter revenue of $339.38 million, up 5.6% year-over-year, and adjusted EPS of $1.14, marking the company's fourth consecutive quarter of beating consensus EPS estimates. The standout driver was the Plasma sub-segment, which generated $155.52 million in revenue with 7.2% reported growth as Haemonetics continued to gain market share, while Blood Management Technologies added $88.12 million at an 8.6% clip and Interventional Technologies returned to growth at $59.94 million, up 2.5%. Recent real-world clinical data supporting the VASCADE MVP XL vascular closure system reinforced the commercial case for the Interventional Technologies portfolio heading into the remainder of the fiscal year. Encouraged by the broad-based momentum, management raised its full-year revenue growth outlook to 5-8% on a reported basis, up from a prior range of 4-7%, while reaffirming expectations for 50-100 basis points of adjusted operating margin expansion and free cash flow conversion of approximately 80%, signaling measured but genuine confidence in the company's trajectory.
Key Takeaways
- • Plasma market share gains driving 8.2% organic growth in Plasma sub-segment
- • Blood Management Technologies sustained momentum with 8.1% organic growth
- • Interventional Technologies returned to growth with 2.8% organic growth
- • Portfolio transformation to higher-margin offerings
- • Favorable working capital adjustments from timing of receivable collections driving significant cash flow improvement
HAE Forward Guidance & Outlook
Haemonetics raised its fiscal 2027 guidance: reported revenue growth of 5-8% (up from 4-7%), organic revenue growth of 4-7% (up from 3-6%), with approximately 2% headwind from 53rd week impact and 0-1% currency impact. Adjusted operating margin expected to expand 50-100 basis points year-over-year. Adjusted EPS growth expected to be comparable to reported revenue growth. Free cash flow conversion expected at approximately 80%. Segment guidance calls for low- to mid-single-digit Apheresis growth (raised from low-single-digit) and mid-single-digit MedSurg growth.
HAE YoY Financials
Q1 2027 vs Q1 2026, source: SEC Filings
HAE Revenue by Segment
With YoY comparisons, source: SEC Filings
“We had a strong start to fiscal 2027, gaining Plasma share, sustaining Blood Management Technologies momentum, and returning Interventional Technologies to growth. With our evolved portfolio, transformed operating model and disciplined execution, we are strengthening our competitive position and demonstrating the durable growth of our diversified businesses. We raised full-year guidance, and Haemonetics is well-positioned to deliver sustainable long-term growth and shareholder value.”
— Chris Simon, Q1 2027 Earnings Press Release
HAE Earnings Trends
HAE vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
HAE EPS Trend
Earnings per share: estimate vs actual
HAE Revenue Trend
Quarterly revenue: estimate vs actual
HAE Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 27 | — | $1.14 | — | $339.4M | — |
| Q4 26 BEAT FY | $1.27 | $1.29 | +1.38% | $346.4M | +2.82% |
| FY Full Year | — | $4.96 | — | $1.33B | — |
| Q3 26 BEAT | $1.25 | $1.31 | +4.77% | $339.0M | +1.88% |
| Q2 26 BEAT | $1.11 | $1.27 | +14.34% | $327.3M | +5.08% |
| Q1 26 BEAT | $1.02 | $1.10 | +8.31% | $321.4M | +5.51% |